Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II.

Détails

ID Serval
serval:BIB_8AFB4F82172E
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II.
Périodique
Journal of the European Academy of Dermatology and Venereology
Auteur(s)
Wollenberg A., Barbarot S., Bieber T., Christen-Zaech S., Deleuran M., Fink-Wagner A., Gieler U., Girolomoni G., Lau S., Muraro A., Czarnecka-Operacz M., Schäfer T., Schmid-Grendelmeier P., Simon D., Szalai Z., Szepietowski J.C., Taïeb A., Torrelo A., Werfel T., Ring J.
Collaborateur(s)
European Dermatology Forum (EDF), the European Academy of Dermatology and Venereology (EADV), the European Academy of Allergy and Clinical Immunology (EAACI), the European Task Force on Atopic Dermatitis (ETFAD), European Federation of Allergy and Airways Diseases Patients’ Associations (EFA), the European Society for Dermatology and Psychiatry (ESDaP), the European Society of Pediatric Dermatology (ESPD), Global Allergy and Asthma European Network (GA2LEN) and the European Union of Medical Specialists (UEMS)
ISSN
1468-3083 (Electronic)
ISSN-L
0926-9959
Statut éditorial
Publié
Date de publication
06/2018
Peer-reviewed
Oui
Volume
32
Numéro
6
Pages
850-878
Langue
anglais
Notes
Publication types: Letter
Publication Status: ppublish
Résumé
This guideline was developed as a joint interdisciplinary European project, including physicians from all relevant disciplines as well as patients. It is a consensus-based guideline, taking available evidence from other guidelines, systematic reviews and published studies into account. This second part of the guideline covers antimicrobial therapy, systemic treatment, allergen-specific immunotherapy, complementary medicine, psychosomatic counselling and educational interventions, whereas the first part covers methods, patient perspective, general measures and avoidance strategies, basic emollient treatment and bathing, dietary intervention, topical anti-inflammatory therapy, phototherapy and antipruritic therapy. Management of AE must consider the individual clinical variability of the disease. Systemic immunosuppressive treatment with cyclosporine, methotrexate, azathioprine and mycophenolic acid is established option for severe refractory cases, and widely available. Biologicals targeting the T helper 2 pathway such as dupilumab may be a safe and effective, disease-modifying alternative when available. Oral drugs such as JAK inhibitors and histamine 4 receptor antagonists are in development. Microbial colonization and superinfection may cause disease exacerbation and can require additional antimicrobial treatment. Allergen-specific immunotherapy with aeroallergens may be considered in selected cases. Psychosomatic counselling is recommended especially in stress-induced exacerbations. Therapeutic patient education ('Eczema school') is recommended for children and adult patients. General measures, basic emollient treatment, bathing, dietary intervention, topical anti-inflammatory therapy, phototherapy and antipruritic therapy have been addressed in the first part of the guideline.
Mots-clé
Adult, Allergens/toxicity, Anti-Infective Agents/therapeutic use, Anti-Inflammatory Agents/therapeutic use, Child, Consensus, Dermatitis, Atopic/diet therapy, Dermatitis, Atopic/drug therapy, Dermatitis, Atopic/microbiology, Dermatitis, Atopic/therapy, Dermatologic Agents/therapeutic use, Eczema/diet therapy, Eczema/drug therapy, Eczema/microbiology, Eczema/therapy, Europe, Humans, Immunosuppressive Agents/therapeutic use, Immunotherapy, Patient Education as Topic, Practice Guidelines as Topic
Pubmed
Web of science
Création de la notice
25/06/2018 11:56
Dernière modification de la notice
14/12/2018 7:26
Données d'usage